Company news
Acrivon Therapeutics, Inc. news in 2024
Acrivon Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
October 16, 2024
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
October 10, 2024
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
September 13, 2024
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
September 9, 2024
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
September 8, 2024
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 12, 2024
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2024
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 13, 2024
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
April 23, 2024
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
April 15, 2024
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resi...
April 9, 2024
Acrivon Therapeutics Announces $130 Million Private Placement Financing
April 8, 2024
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 27, 2024
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
March 4, 2024
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
March 3, 2024
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
February 26, 2024
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
February 7, 2024
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 5, 2024
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 11, 2024
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
January 2, 2024
Decks in 2024
- Technical Presentation (September 2024)
Technical · 45 slides · Sep 16, 2024
- Investor Day (April 2024)
Investor day · 42 slides · Apr 24, 2024
- Investor Presentation (January 2024)
Investor deck · 60 slides · Jan 8, 2024